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Abstract: A 34-year-old man presented to the hospital with right-sided headache. He was diagnosed with GBM. He underwent resec-
tion of the tumor with placement of carmustine impregnated wafers. Then he underwent adjuvant chemotherapy with temozolamide. 
Before the completion of chemotherapy he had a recurrence. He underwent re-resection with placement of carmustine impregnated 
wafers. Subsequently he had eighteen cycles of salvage biochemotherapy with bevacizumab and irinotecan. To date, routine MRI scans 
of the brain have not shown evidence of recurrence. He continues to be in remission three years after treatment with bevacizumab and 
irinotecan.
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Introduction
Glioblastoma multiforme (GBM) is the most   common 
primary brain tumor in adults.1 There are about 12,000 
to 14,000 cases of GBM diagnosed annually in the 
United States.2 Despite aggressive multidisciplinary 
treatment approaches, the prognosis for GBM is poor, 
with a median survival of approximately 15 months 
and less than a 10% 5-year survival rate.3   Furthermore, 
the prognosis for recurrent GBM is   dismal, with a 
median survival of 4 to 6 months and less than a 5% 
survival rate at 5 years.4,5
Currently, the standard of care for the   treatment 
of newly-diagnosed GBM is surgical resection, fol-
lowed by concurrent radiation therapy with temozo-
lomide, completed by adjuvant chemotherapy with 
temozolomide.6  The  addition  of  temozolomide  to 
radiation  therapy  has  improved  survival,  although 
benefit from the addition of temozolomide is primarily 
restricted to patients with a tumor with a methylated 
promoter  of  methyl-guanine  methyl  transferase 
(MGMT).7 However, 45% to 55% of primary GBMs 
have an unmethylated MGMT promoter, and these 
patients have a worse prognosis.
Despite the survival benefit associated with   surgery, 
adjuvant  radiation  therapy  and    chemotherapy,  the 
majority of patients relapse   following   initial therapy. 
The optimal management for patients with recurrent 
or progressive GBM is unclear. In   general, treatment 
for recurrent GBM may involve repeated   resection, 
focal  irradiation,  and  systemic  or  experimental 
  therapies. Patients with recurrent GBM often undergo 
serial    salvage  therapies,  but  the    decision  about 
which    treatments  to  pursue  and  in  what  sequence 
depends on specific factors related to each patient and 
tumor.
Since  1976,  carmustine  impregnated  wafers 
(Gliadel®) is the last chemotherapy approved for use 
as an adjunct to surgery to prolong survival in patients 
with  recurrent  GBM  for  whom  surgical    resection 
is  indicated.  In  May  2009,  the  FDA  approved  the 
use  of  bevacizumab  for  the  treatment  of  progres-
sive GBM despite treatment. Until bevacizumab, all 
other  experimental  therapies  tested  in  recurrent  or 
  progressive GBM failed to meet the FDA guidelines 
for approval.
We report a case of a patient with recurrent GBM 
who continues to be in remission three years after 
  re-resection  followed  by  biochemotherapy  with 
  bevacizumab and irinotecan.
case presentation
The patient is a 34-year-old healthy man with no 
  significant past medical history who presented to the 
hospital with severe right-sided   headache and visual 
disturbances in October 2005. He had a   magnetic 
resonance  imaging  scan  (MRI)  of  the  brain  with 
  gadolinium that revealed a large right temporoparietal 
hemorrhagic mass highly suggestive of a primary 
brain  neoplasm  (Fig.  1).  CT  scan  of  the  chest, 
  abdomen, and pelvis with IV contrast were   negative 
for  a    primary  tumor.  The  patient  subsequently 
underwent a   craniotomy and resection of the tumor 
with placement of carmustine impregnated wafers 
(Gliadel®). Post-surgically the patient recovered well 
and  the  pathology  report  revealed  GBM.  Shortly 
after  recuperation  from  his  surgery,  the  patient 
was treated with radiation therapy and concurrent 
  temozolomide  at  75  mg/m2  daily  for  the  6-week 
  duration of his   radiation therapy. He was also placed 
on   dexamethasone simultaneously. The patient tol-
Figure 1. MrI of brain with gadolinium showing a large right temporopa-
rietal hemorrhagic mass (arrow).recurrent GBM treated with bevacizumab
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erated the radiation with concurrent chemotherapy 
well. His neurological status was intact except for one 
episode of seizure for which he was given levetirac-
etam. After completion of radiation therapy, MRI of 
the brain demonstrated postoperative changes with 
  surgical margin enhancement and diffuse T2 changes 
consistent with edema and/or non-enhancing neo-
plasm with no evidence midline shift or mass effect 
(Fig. 2). The patient was treated with two cycles of 
temozolomide at 300 mg/m2 daily for 5 days. After 
his  second  cycle  of  temozolomide,  a  MRI  of  the 
brain with gadolinium revealed diminishment in the 
postoperative cavity as well as enhancement along 
the  margins  consistent  with  response  to  therapy. 
He completed the adjuvant chemotherapy with three 
more cycles of temozolomide at 300 mg/m2 daily 
for 5 days. In August 2006, ten months after the 
diagnosis  of  GBM  and  before  the  completion  of 
adjuvant chemotherapy, the patient returned to the 
office with complaints of blurred vision. MRI of the 
brain with gadolinium showed   progressive disease 
with focus of enhancement seen inferomedially to 
Figure 2. MrI of brain with gadolinium showing postoperative changes 
with  surgical  margin  enhancement,  edema  and/or  non-enhancing 
  neoplasm (arrow).
the surgical cavity associated with edema extending 
to the right basal ganglia, right temporal lobe and 
right thalamus (Fig. 3). At that point the patient had a 
recurrence. He underwent   re-resection with   placement 
of carmustine impregnated wafers (Gliadel®). MRI 
with gadolinium demonstrated postsurgical changes 
within the right temporal lobe with no significant 
mass effect or midline shift (Fig. 4). The pathology 
report revealed GBM. Post-  operatively he was started 
on  salvage  biochemotherapy.  Beginning  October 
2006, he underwent treatment with four cycles of 
irinotecan and bevacizumab. He tolerated the chemo-
therapy well except for an acneiform rash involving 
the face and the upper chest for which he was treated 
with topical clindamycin. Repeat MRI of the brain 
with gadolinium showed diffuse, marked increase 
in T2 hyperintensity without enhancement diffusely 
involving the right parietal and frontal parenchyma. 
There was also mild enlargement of the ventricular 
system, diffuse effacement of the right hemispheric 
sulci and mass effect indicating progression since the 
prior study. He was continued on two more cycles 
Figure 3. MrI of brain with gadolinium showing new heterogeneously 
enhancing lesion adjacent to the surgical bed within the right temporal 
lobe consistent with recurrent neoplasm (arrow).Vivekanandarajah et al
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of irinotecan and bevacizumab. After six cycles of 
bevacizumab and irinotecan, PET/CT scan   (positron 
emission scan/computed tomography) of the head 
that showed a large   photopenic area   consistent with 
post treatment defect. He was continued on ten more 
cycles  of  irinotecan  and  bevacizumab.  A  repeat 
PET  scan  was  done  and  showed  no  evidence  of 
metabolically  active  tumor.  He  was  continued  on 
two  more  cycles  of  irinotecan  and  bevacizumab. 
In August  2007,  after  completing  eighteen  cycles 
of  bevacizumab  and  irinotecan  over  a  period  of 
ten months, it was decided to terminate the chemo-
therapy since the patient’s neurological status was 
stable and repeat MRI and PET/CT scans showed 
no   evidence of recurrence or metabolically active 
tumor (Fig. 5).
The  patient  has  been  on  levetiracetam  and  his 
  neurological status has been stable until now. He has 
been followed up at the office every 6 months and 
serial MRIs of the brain have shown no recurrence of 
the tumor. To date, it has been 3 years after the patient’s 
last  dose  of  biochemotherapy  with  irinotecan  and 
bevacizumab for recurrent glioblastoma   multiforme. 
Thus he is considered to be in remission.
Figure 4. MrI of brain with gadolinium showing postsurgical changes 
within the right temporal lobe with no significant mass effect or midline 
shift (arrow).
Figure  5.  MrI  of  brain  with  gadolinium  showing  overall  decrease  in   
midline shift and edema with no evidence of recurrence (arrow).
Discussion
Glioblastoma  multiforme  (GBM)  is  a  rapidly  pro-
gressive  brain  tumor  that  is  best  managed  with  a 
combined modality approach incorporating maximal 
surgical  resection,  adjuvant  postoperative  radiation 
therapy with concurrent temozolomide, and adjuvant 
temozolomide. The prognosis of patients diagnosed 
with this deadly brain tumor is grim even if a multi-
disciplinary aggressive treatment approach is utilized. 
Temporary remission is only achieved in majority of 
the patients. Despite the use of a combined modality 
approach, most patients eventually relapse after   initial 
therapy.
The optimal management for patients with recur-
rent or progressive GBM is unclear, and there are 
no  randomized  trials  that  directly  compare  active 
intervention  versus  supportive  care.  The  value  of 
  re-intervention at the time of relapse was   suggested 
in  a  retrospective  review  of  168  patients  with 
recurrent GBM who were treated at a single center. 
Patients undergoing re-intervention were more likely 
to have a higher     progression free survival (PFS) at 
12 months (21 versus 8 percent), and to be alive at 
both one year (71 versus 15 percent) and two years recurrent GBM treated with bevacizumab
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(32   versus 5 percent).8 One of the most important 
prognostic  factors  for  benefit  from  re-intervention 
for recurrent GBM is the   pre-treatment performance 
status.9–12  Other  factors  that  contribute  to  the  ben-
efit from second-line therapy include the volume of 
residual disease, the histologic grade (both at initial 
therapy and at recurrence), the relapse-free interval, 
and   recurrence pattern (local versus diffuse). As per 
the  NCCN    clinical  practical  guidelines  in  oncol-
ogy, management of locally recurrent GBM includes 
  re-resection and impregnation of carmustine   polymers 
followed by systemic chemotherapy/re-radiation or 
re-resection  followed  by  systemic  chemotherapy/
re-radiation. Management of locally recurrent GBM 
that is not amenable to resection includes systemic 
chemotherapy, radiation, brachitherapy or supportive 
care if poor performance status.
The surgical management of recurrent GBM is 
controversial. The indications for a debulking re-
operation in a patient with recurrent disease are not 
firmly established. Recent studies have   suggested 
that  re-operation  provides  a  3–5  month  median 
survival,  without  significant  increase  in  morbid-
ity and mortality.13 Several studies have concluded 
that   prolongation of survival time after re-operation 
was statistically   significant in the Karnofsky perfor-
mance subgroup (60 or greater).7,8 Other favorable 
prognostic variables include young age (,=50), a 
longer interval since the original surgery, and the 
extent of the second   surgical resection. Re-resec-
tion improves symptoms, maintains quality of life, 
delays symptom progression, reduces corticosteroid 
doses and also improves response to chemotherapy 
and/or radiotherapy. Thus, surgical re-resection in 
recurrent  GBM  should  be  considered  in  selected 
patients.
Carmustine  impregnated  wafers  (Gliadel®)  may 
prolong  survival  in  locally  recurrent  GBM  after 
  re-resection. In a phase III trial in which, patients 
were randomly assigned to have either carmustine or 
placebo impregnated wafers into the tumor site   during 
surgery for locally recurrent disease, it was found that 
the carmustine wafer group had a significantly longer 
median survival (31 versus 23 weeks with placebo).2,14 
Although it was found that carmustine impregnated 
wafers  play  a  vital  role  in  recurrent  GBM,  many 
patients are not candidates for a repeat gliadel wafer 
placement.
Irinotecan  is  a  topoisomerase-1  inhibitor  with 
excellent  penetration  into  the  central  nervous 
  system.14  It  has  a  different  mechanism  of  action 
than    alkylating  agents  such  as  temozolomide, 
carmustine,  and  lomustine  and  has  demonstrated 
  modest    activity  in  recurrent  GBM  with  response 
rates of 0% to 17%.15–18 The 6-month progression-
free   survival is less than 20% when irinotecan is 
used as a single agent for recurrent GBM.18,19 Thus, 
there is the need for combination chemotherapy in 
recurrent GBM.
The pathognomic features of GBM are the pres-
ence of necrosis and vascular proliferation. In May 
2009, the US Food and Drug Administration approved 
  bevacizumab as a single agent for patients with GBM 
with  progressive  disease  despite  treatment  with 
other therapies. It is a monoclonal antibody to vas-
cular  endothelial  growth  factor,  which  is  strongly 
expressed in GBM tumor cells. Although this over-
expression is associated with a poor prognosis, it also 
provides a target that can be blocked by bevacizumab. 
  Bevacizumab  was  approved  for  use  in  selected 
patients with GBM based on the results of two single-
arm trials, AVF3708g and NCI 06-C-0064E.
The  most  recent  trial,  known  as  AVF3708g 
(BRAIN)  evaluated  167  patients  with  GBM  who 
had  progressed  on  radiation  and  temozolomide. 
This was a phase II, multicenter, open-label, non- 
comparative  trial.  The  patients  were  randomly 
assigned to receive bevacizumab 10 mg/kg alone 
or  in  combination  with  irinotecan  340  mg/m2  or 
125 mg/m2 (with or without concomitant enzyme-
inducing  antiepileptic  drugs)  every  2  weeks. The 
primary  endpoints  were  6-month  PFS  and  objec-
tive response rate. The secondary endpoints were 
safety  and  overall  survival.  The  results  revealed 
that the estimated 6-month PFS rates were 42.6% 
for the bevacizumab group and 50.3% for the beva-
cizumab plus irinotecan group. The median overall 
survival times (OST) were 9.2 months for the beva-
cizumab group and 8.7 months for the bevacizumab 
plus irinotecan group. The overall conclusion of the 
study was that bevacizumab alone or in combination 
with irinotecan was fairly well tolerated and highly 
efficacious in recurrent GBM.19
The second trial known as the NCI 06-C-0064E 
was based on a single-arm, single-site study of 56 
patients who had disease progression after receiving Vivekanandarajah et al
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temozolomide and radiation therapy. These patients 
received bevacizumab (10 mg/kg IV) every 2 weeks 
until disease progression or unacceptable toxicity was 
noted. The objective response rate was 19.6% and the 
median response duration was 3.9 months.19
There  was  also  another  retrospective  study  that 
was conducted at Henry Ford Hermelin Brain Tumor 
Center from 11/15/2005 to 04/01/2008 on 51 patients 
with recurrent high-grade gliomas treated with beva-
cizumab plus irinotecan. It was done to   determine the 
efficacy, safety and patterns of responses, and occur-
rences in patients with recurrent high-grade gliomas 
treated with bevacizumab plus irinotecan. The results 
showed  that  the  median  progression  free  survival 
(PFS) time was 7.6 months, the 6-month PFS rate 
was 63.7%, the overall survival rate (OS) at 6 months 
was 78.0% and the 12-month OS rate was 42.6% for 
recurrent GBM.20
conclusion
GBM is a very aggressive malignancy that has a dis-
mal prognosis despite combined modality treatment 
approaches  with  surgery,  radiotherapy  and  chemo-
therapy. The recurrence is inevitable; its management 
is often unclear and case dependent.
We can conclude that the survival rate was improved 
in patients treated with irinotecan and bevacizumab 
compared  with  historical  controls.  It  is  unclear  if 
irinotecan  is  the  optimal  chemotherapy,  although 
studies have demonstrated that patients with recurrent 
high grade gliomas treated with the combination of 
bevacizumab  and  irinotecan  demonstrate  improved 
clinical outcome when   compared to   historical data. 
There is marked clinical benefit with the inclusion 
of bevacizumab in treatment regimens for   recurrent 
GBM,  as  demonstrated  by  several  trials.  The 
  anti-VEGF effect of bevacizumab is likely responsible 
for the clinical improvements.
We  can  conclude  that  this  patient  remains  in 
remission  3  years  after  the  initiation  of  salvage 
  biochemotherapy consisting of bevacizumab and iri-
notecan. We can confidently report that his response 
and overall survival time exceeds by far of what is 
reported in the literature. It is also important to   mention 
that the recurrence occurred after ten months of the 
diagnosis of GBM before the   completion of adjuvant 
chemotherapy.  As  mentioned  above,    studies  have 
revealed that the maximum median overall   survival 
for patients with recurrent GBM is 9 months. The age 
of this patient and the high Karnofsky   performance 
status are good prognostic features and certainly con-
tribute to the continued remission. It is possible that 
re-resection would also have played a pivotal role in 
addition to bevacizumab in maintaining the extended 
remission.
Currently there are no randomized clinical   trials 
that  directly  compare  active  intervention  versus 
supportive care in the overall survival of recurrent 
GBM.  Future  research  may  be  directed  towards 
investigating the overall survival in patients opting 
for comfort care in recurrent GBM.
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